<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2026-185</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-10216</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЗАБОЛЕВАНИЯ КИШЕЧНИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BOWEL DISEASES</subject></subj-group></article-categories><title-group><article-title>Применение отилония бромида в терапии абдоминальной боли</article-title><trans-title-group xml:lang="en"><trans-title>Use of otilonium bromide in the treatment of abdominal pain</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3125-6282</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пахомова</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Pakhomova</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пахомова Инна Григорьевна - к.м.н., доцент кафедры факультетской терапии с клиникой.</p><p>197341, Санкт-Петербург, ул. Аккуратова, д. 2</p></bio><bio xml:lang="en"><p>Inna G. Pakhomova - Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy with Clinic.</p><p>2, Akkuratov St., St Petersburg, 197341</p></bio><email xlink:type="simple">pakhomova-inna@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр имени В.А. Алмазова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>01</day><month>07</month><year>2026</year></pub-date><volume>0</volume><issue>8</issue><fpage>164</fpage><lpage>169</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Пахомова И.Г., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Пахомова И.Г.</copyright-holder><copyright-holder xml:lang="en">Pakhomova I.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/10216">https://www.med-sovet.pro/jour/article/view/10216</self-uri><abstract><p>Абдоминальная боль встречается достаточно часто в практике врача-клинициста и является серьезной клинической проблемой. Причины абдоминальной боли могут быть различными (как функциональными, так и органическими). Абдоминальная боль является основным проявлением при синдроме раздраженного кишечника (СРК) и в первую очередь связана со спазмом гладкой мускулатуры кишечника. Вместе с тем абдоминальная боль, обусловленная спазмом, может встречаться и при некоторых иных заболеваниях, таких как патология билиарной системы, а именно функциональные расстройства желчного пузыря и сфинктера Одди, болезненные спазмы отделов толстой кишки при СРК-подобных проявлениях на фоне имеющейся органической патологии кишечника в стадии ремиссии (дивертикулярная болезнь, воспалительные заболевания кишечника в стадии ремиссии и некоторые другие). Препаратами выбора при абдоминальной боли со спастическим компонентом являются спазмолитики. Отечественный фармацевтический рынок представлен разными группами спазмолитиков, среди которых можно выделить селективные блокаторы кальциевых каналов. Представителем последних является препарат отилония бромид, который широко используется во всем мире, является эффективным, хорошо переносится и превосходит плацебо в отношении уменьшения симптомов и предотвращения рецидива боли у пациентов как с СРК, так и в купировании спастических проявлений со стороны кишечника иной этиологии. Селективность действия и низкая абсорбция препарата в кишечнике обуславливает минимальное количество побочных эффектов и возможности применения отилония бромида у коморбидных пациентов, в т. ч. и длительно. В статье представлены два клинических случая с проявлением болевого абдоминального синдрома: пациентки с длительным анамнезом СРК и пациента, страдающего неосложненной дивертикулярной болезнью с СРК-подобными проявлениями, в которых отражено место применения отилония бромида.</p></abstract><trans-abstract xml:lang="en"><p>Abdominal pain is a fairly common clinical problem encountered by clinicians. The causes of abdominal pain can be varied (both functional and organic). Abdominal pain is a fairly common clinical problem and is a serious issue in internal medicine and gastroenterology. Abdominal pain is the primary symptom of irritable bowel syndrome (IBS) and is primarily associated with intestinal smooth muscle spasm. However, abdominal pain caused by spasm can also occur with other conditions, such as biliary system disorders, specifically functional disorders of the gallbladder and sphincter of Oddi, and painful colonic spasms associated with IBS-like symptoms associated with underlying organic bowel pathology in remission (diverticular disease, inflammatory bowel disease in remission, and others). Antispasmodics are the drugs of choice for abdominal pain with a spastic component. The domestic pharmaceutical market offers various classes of antispasmodics, including selective calcium channel blockers. One such selective calcium channel blocker is otilonium bromide, which is widely used worldwide. It is effective, well-tolerated, and superior to placebo in reducing symptoms and preventing pain recurrence in patients with both IBS and other intestinal spasticity. The drug’s selective action and low intestinal absorption result in minimal side effects and the potential for otilonium bromide use in patients with comorbidities, including long-term use. This article presents two clinical cases of abdominal pain: a female patient with a long history of IBS and a patient with uncomplicated diverticular disease with IBS-like manifestations. These cases highlight the potential use of otilonium bromide.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>спазм</kwd><kwd>функциональные расстройства</kwd><kwd>синдром раздраженного кишечника</kwd><kwd>спазмолитики</kwd><kwd>блокаторы кальциевых каналов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>spasm</kwd><kwd>functional disorders</kwd><kwd>irritable bowel syndrome</kwd><kwd>antispasmodics</kwd><kwd>calcium channel blockers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114. https://doi.org/10.1053/j.gastro.2020.04.014.</mixed-citation><mixed-citation xml:lang="en">Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114. https://doi.org/10.1053/j.gastro.2020.04.014.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин ВТ, Шелыгин ЮА, Баранов АА, Намазова-Баранова ЛС, Ачкасов СИ, Алексеева ОП и др. Синдром раздраженного кишечника: клинические рекомендации. М.; 2024. 64 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/892_1.</mixed-citation><mixed-citation xml:lang="en">Ивашкин ВТ, Шелыгин ЮА, Баранов АА, Намазова-Баранова ЛС, Ачкасов СИ, Алексеева ОП и др. Синдром раздраженного кишечника: клинические рекомендации. М.; 2024. 64 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/892_1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин ВТ, Шептулин АА. Боли в животе. М.: МЕДпресс-информ; 2012. 112 с.</mixed-citation><mixed-citation xml:lang="en">Ивашкин ВТ, Шептулин АА. Боли в животе. М.: МЕДпресс-информ; 2012. 112 с.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lindberg G, Mohammadian G. Loose ends in the differential diagnosis of IBS-like symptoms. Front Med. 2023;10:1141035. https://doi.org/10.3389/fmed.2023.1141035.</mixed-citation><mixed-citation xml:lang="en">Lindberg G, Mohammadian G. Loose ends in the differential diagnosis of IBS-like symptoms. Front Med. 2023;10:1141035. https://doi.org/10.3389/fmed.2023.1141035.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yu V, Ballou S, Hassan R, Singh P, Shah E, Rangan V et al. Abdominal pain and depression, not bowel habits, predict health care utilization in patients with functional bowel disorders. Am J Gastroenterol. 2021;116(8):1720–1726. https://doi.org/10.14309/ajg.0000000000001306.</mixed-citation><mixed-citation xml:lang="en">Yu V, Ballou S, Hassan R, Singh P, Shah E, Rangan V et al. Abdominal pain and depression, not bowel habits, predict health care utilization in patients with functional bowel disorders. Am J Gastroenterol. 2021;116(8):1720–1726. https://doi.org/10.14309/ajg.0000000000001306.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Яковенко ЭП, Яковенко АВ, Агафонова НА, Иванов АН, Прянишникова АС, Попова ЕВ, Григорьева ЮВ. Абдоминальные боли: механизмы формирования, рациональный подход к выбору терапии. РМЖ. 2009;(2):48–53. Режим доступа: https://www.rmj.ru/articles/bolezni_organov_pishchevareniya/Abdominalynye_boli_mehanizmy_formirovaniya_racionalynyy_podhod_k_vyboru_terapii/.</mixed-citation><mixed-citation xml:lang="en">Yakovenko EP, Yakovenko AV, Agafonova NA, Ivanov AN, Pryanishnikova AS, Popova EV, Grigorieva SW. Abdominal pain: mechanisms of formation, rational approach to the choice of therapy. RMJ. 2009;(2):48–53. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_organov_pishchevareniya/Abdominalynye_boli_mehanizmy_formirovaniya_racionalynyy_podhod_k_vyboru_terapii/.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Weinstein WM, Hawkey CJ, Bosch J. Clinical Gastroenterology and Hepatology. Elsevie; 2005. 1191 p.</mixed-citation><mixed-citation xml:lang="en">Weinstein WM, Hawkey CJ, Bosch J. Clinical Gastroenterology and Hepatology. Elsevie; 2005. 1191 p.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Пахомова ИГ. Заболевания толстой кишки: от функциональных расстройств к органической патологии. Медицинский совет. 2013;(5):46–53. https://doi.org/10.21518/2079-701X-2013-5-46-53.</mixed-citation><mixed-citation xml:lang="en">Pakhomova IG. Pathology of the colon: from functional to organic. Meditsinskiy Sovet. 2013;(5):46–53. (In Russ.) https://doi.org/10.21518/2079-701X-2013-5-46-53.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–917. https://doi.org/10.1016/S2468-1253(20)30217-X.</mixed-citation><mixed-citation xml:lang="en">Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–917. https://doi.org/10.1016/S2468-1253(20)30217-X.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Triantafillidis JK, Malgarinos G. Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review. Clin Exp Gastroenterol. 2014;7:75–82. https://doi.org/10.2147/CEG.S46291.</mixed-citation><mixed-citation xml:lang="en">Triantafillidis JK, Malgarinos G. Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review. Clin Exp Gastroenterol. 2014;7:75–82. https://doi.org/10.2147/CEG.S46291.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome Aliment Pharmacol Ther. 2011;34(4):432–442. https://doi.org/10.1111/j.1365-2036.2011.04730.x.</mixed-citation><mixed-citation xml:lang="en">Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome Aliment Pharmacol Ther. 2011;34(4):432–442. https://doi.org/10.1111/j.1365-2036.2011.04730.x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14(12):1331–1338. https://doi.org/10.1097/00042737-200212000-00008.</mixed-citation><mixed-citation xml:lang="en">Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14(12):1331–1338. https://doi.org/10.1097/00042737-200212000-00008.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Weiser T. Guideline recommendations for the treatment of abdominal pain (in irritable bowel syndrome). EFSM. 2021;1:210010. https://doi.org/10.52778/efsm.21.0010.</mixed-citation><mixed-citation xml:lang="en">Weiser T. Guideline recommendations for the treatment of abdominal pain (in irritable bowel syndrome). EFSM. 2021;1:210010. https://doi.org/10.52778/efsm.21.0010.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(Suppl. 2):1–18. https://doi.org/10.1038/s41395-018-0084-x.</mixed-citation><mixed-citation xml:lang="en">Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(Suppl. 2):1–18. https://doi.org/10.1038/s41395-018-0084-x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Carmona-Sánchez R, Icaza-Chávez ME, Bielsa-Fernández MV, Gómez-Escudero O, Bosques-Padilla F, Coss-Adame E et al. The Mexican consensus on irritable bowel syndrome. Rev Gastroenterol Mex. 2016;81(3):149–167. https://doi.org/10.1016/j.rgmx.2016.01.004.</mixed-citation><mixed-citation xml:lang="en">Carmona-Sánchez R, Icaza-Chávez ME, Bielsa-Fernández MV, Gómez-Escudero O, Bosques-Padilla F, Coss-Adame E et al. The Mexican consensus on irritable bowel syndrome. Rev Gastroenterol Mex. 2016;81(3):149–167. https://doi.org/10.1016/j.rgmx.2016.01.004.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD et al. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24(2):197–215. https://doi.org/10.5056/jnm17145.</mixed-citation><mixed-citation xml:lang="en">Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD et al. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24(2):197–215. https://doi.org/10.5056/jnm17145.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol. 2011;49(2):237–293. https://doi.org/10.1055/s-0029-1245976.</mixed-citation><mixed-citation xml:lang="en">Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol. 2011;49(2):237–293. https://doi.org/10.1055/s-0029-1245976.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018;13(4):259–288. https://doi.org/10.5114/pg.2018.78343.</mixed-citation><mixed-citation xml:lang="en">Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018;13(4):259–288. https://doi.org/10.5114/pg.2018.78343.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E et al. Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332–363. https://doi.org/10.17235/reed.2016.4389/2016.</mixed-citation><mixed-citation xml:lang="en">Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E et al. Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332–363. https://doi.org/10.17235/reed.2016.4389/2016.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Хруцкая МС, Семеняко СВ, Бобровская ЕИ, Парфененко ТВ. Влияние отилония бромида на интенсивность хронической абдоминальной боли. Медицинские новости. 2014;(3):59–61. Режим доступа: https://www.elibrary.ru/salivv.</mixed-citation><mixed-citation xml:lang="en">Khrutskaya MS, Semenyako SV, Bobrovskaya EI, Parfenenko TV. Еffect of otilonium bromide on intensity of chronic abdominal pain. Meditsinskie Novosti. 2014;(3):59–61. (In Russ.) Available at: https://www.elibrary.ru/salivv.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou L, She P, Tan F, Li S, Zeng X, Chen L et al. Repurposing Antispasmodic Agent Otilonium Bromide for Treatment of Staphylococcus aureus Infections. Front Microbiol. 2020;11:1720. https://doi.org/10.3389/fmicb.2020.01720.</mixed-citation><mixed-citation xml:lang="en">Zhou L, She P, Tan F, Li S, Zeng X, Chen L et al. Repurposing Antispasmodic Agent Otilonium Bromide for Treatment of Staphylococcus aureus Infections. Front Microbiol. 2020;11:1720. https://doi.org/10.3389/fmicb.2020.01720.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Zhen C, Wang L, Feng Y, Whiteway M, Hang S, Yu J et al. Otilonium Bromide Exhibits Potent Antifungal Effects by Blocking Ergosterol Plasma Membrane Localization and Triggering Cytotoxic Autophagy in Candida Albicans. Adv Sci. 2024;11(35):e2406473. https://doi.org/10.1002/advs.202406473.</mixed-citation><mixed-citation xml:lang="en">Zhen C, Wang L, Feng Y, Whiteway M, Hang S, Yu J et al. Otilonium Bromide Exhibits Potent Antifungal Effects by Blocking Ergosterol Plasma Membrane Localization and Triggering Cytotoxic Autophagy in Candida Albicans. Adv Sci. 2024;11(35):e2406473. https://doi.org/10.1002/advs.202406473.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031–6043. https://doi.org/10.3748/wjg.v20.i20.6031.</mixed-citation><mixed-citation xml:lang="en">Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031–6043. https://doi.org/10.3748/wjg.v20.i20.6031.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Clavé P, Tack J. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. Ther Adv Gastroenterol. 2017;10(3):311–322. https://doi.org/10.1177/1756283X16681708.</mixed-citation><mixed-citation xml:lang="en">Clavé P, Tack J. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. Ther Adv Gastroenterol. 2017;10(3):311–322. https://doi.org/10.1177/1756283X16681708.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
